Incyte Corporation (LON: 0J9P)

Market Cap	11.33B
Revenue (ttm)	3.04B
Net Income (ttm)	24.23M
Shares Out	n/a
EPS (ttm)	0.11
PE Ratio	467.37
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,808
Average Volume	1,606
Open	73.47
Previous Close	72.86
Day's Range	72.03 - 73.47
52-Week Range	50.81 - 75.42
Beta	0.71
RSI	52.37
Earnings Date	Feb 4, 2025

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast ...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1991
• Employees: 2,524
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0J9P

Financial Performance

In 2023, Incyte's revenue was $3.70 billion, an increase of 8.87% compared to the previous year's $3.39 billion. Earnings were $597.60 million, an increase of 75.42%.

Financial numbers in USD